68 completed, 14 terminated, 6 recruiting, 3 unknown. 46 Phase 2, 35 Phase 1, 13 Phase 3, 1 Phase 4.
Follow PharmaMar: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies PM54, Irinotecan, Doxorubicin - Advanced Solid Tumor | Phase 1 / Phase 2 | Not yet recruiting | PharmaMar | 231 | 2026-11-12 | 2026-09-24 |
| Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies Pembrolizumab, PM54 - Advanced Malignancies | Phase 1 / Phase 2 | Recruiting | PharmaMar | 119 | 2026-05-21 | 2026-10-13 |
| Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC) Plitidepsin 1.5 mg/day, Placebo, Placebo and Plitidepsin 1.5mg/day - Post COVID-19 Condition, Long COVID Syndrome | Phase 2 | Completed | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 90 | 2025-02-07 | 2026-10-08 |
| Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour Doxorubicin, Trabectedin - Leiomyosarcoma Uterus | Phase 2 | Recruiting | UNICANCER | 198 | 2025-01-27 | 2026-09-29 |
| Prospective Study to Evaluate Patient Reported Outcomes (PRO) During Rechallenge With Trabectedin in Sarcoma Patients Soft Tissue Sarcoma | Terminated | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 7 | 2023-10-31 | 2025-12-01 | |
| Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer Association of lurbinectedin and durvalumab, Association of carboplatin and etoposide - Small Cell Lung Cancer, Platinum-Sensitive Lung Small Cell Carcinoma | Phase 2 | Withdrawn | Institut Bergonié | 2023-10-01 | 2024-06-05 | |
| Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) Lurbinectedin, Doxorubicin - Leiomyosarcoma | Phase 3 | Active not recruiting | PharmaMar | 469 | 2023-09-21 | 2026-06-18 |
| Clinical Trial of PM54 in Advanced Solid Tumors Patients. PM54 - Advanced Solid Tumor | Phase 1 | Recruiting | PharmaMar | 125 | 2023-04-28 | 2025-09-24 |
| Plitidepsin Versus Control in Immunocompromised Adult Participants With Symptomatic COVID-19 Requiring Hospital Care (NEREIDA) Plitidepsin - COVID-19 | Phase 2 | Terminated | PharmaMar | 37 | 2023-04-19 | 2024-12-02 |
| PM534 Administered Intravenously to Patients With Advanced Solid Tumors PM534 - Patients With Advanced Solid Tumors | Phase 1 | Recruiting | PharmaMar | 30 | 2022-12-23 | 2025-08-22 |
| Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) Irinotecan, Lurbinectedin, Topotecan - Relapsed Small Cell Lung Cancer | Phase 3 | Completed | PharmaMar | 705 | 2022-07-22 | 2026-10-21 |
| RW Effectiveness of Lurbinectedin in Extensive Stage SCLC Lurbinectedin - Small-cell Lung Cancer | Completed | Intergroupe Francophone de Cancerologie Thoracique | 312 | 2022-04-01 | 2023-01-06 | |
| Extension Study in a Cohort of Adult Patients With COVID-19 Infection Plitidepsin 1.5 mg / day, Plitidepsin 2.0 mg / day, Plitidepsin 2.5 mg / day - COVID-19 Infection | Phase 1 / Phase 2 | Completed | PharmaMar | 34 | 2022-01-25 | 2024-12-31 |
| Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma Trabectedin, Gemcitabine, No Intervention: Observational Cohort - Leiomyosarcoma of Ovary, Soft Tissue Sarcoma | Phase 2 | Recruiting | Italian Sarcoma Group | 100 | 2021-10-29 | 2026-03-25 |
| Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma Trabectedin - Mesenchymal Chondrosarcoma | Phase 2 | Recruiting | Italian Sarcoma Group | 16 | 2021-09-14 | 2026-03-27 |
| Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection Plitidepsin, Dexamethasone, Remdesivir - COVID-19 Infection | Phase 3 | Terminated | PharmaMar | 205 | 2021-06-04 | 2025-02-21 |
| Clinical Pharmacokinetic Study of Lurbinectedin in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Impairment Lurbinectedin - Advanced Solid Tumor, Hepatic Impairment | Phase 1 | Unknown | PharmaMar | 24 | 2021-03-09 | 2023-11-27 |
| Study to Evaluate the Effect of Bosentan on the Pharmacokinetics of Lurbinectedin in Patients With Advanced Solid Tumors Lurbinectedin, Bosentan - Advanced Solid Tumor | Phase 1 | Completed | PharmaMar | 11 | 2021-01-14 | 2025-09-16 |
| Clinical Trial of Lurbinectedin (PM01183) in Patients With Advanced Solid Tumors Lurbinectedin alone, Lurbinectedin+Itraconazole co-administration - Advanced Solid Tumors | Phase 1 | Completed | PharmaMar | 14 | 2020-10-07 | 2025-09-02 |
| Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer. Lurbinectedin, Pembrolizumab - Small Cell Lung Carcinoma | Phase 1 / Phase 2 | Completed | Antonio Calles Blanco | 28 | 2020-09-21 | 2025-06-04 |
Showing 20 of 95. Sign in to see all of them.
Neoplasms (19) · Sarcoma (17) · Ovarian Neoplasms (14) · Breast Neoplasms (7) · Small Cell Lung Carcinoma (6) · COVID-19 (5) · Leiomyosarcoma (5) · Endometrial Neoplasms (4) · Liposarcoma (4) · Lymphoma (4) · Multiple Myeloma (4) · Neoplasm Metastasis (4) · Recurrence (4) · Leukemia (3) · Prostatic Neoplasms (3)
Trabectedin (31) · PM 01183 (24) · plitidepsin (16) · Dexamethasone (14) · Doxorubicin (8) · Gemcitabine (7) · liposomal doxorubicin (5) · olaparib (4) · Irinotecan (3) · PM 00104 (3) · Topotecan (3) · plocabulin (3) · Bortezomib (2) · Carboplatin (2) · Docetaxel (2)
United States (46) · Spain (42) · France (30) · Italy (22) · Germany (20) · Belgium (15) · United Kingdom (14) · Poland (9) · Switzerland (9) · Netherlands (8) · Canada (7) · Australia (6) · Austria (5) · Brazil (5) · Portugal (5)
Daniel Pink, MD (2) · Mark Ratain, MD (2) · Rubin Lubomirov, MD, PhD (2) · A J Gelderblom, Prof (1) · Andres Poveda, MD (1) · Angiolo Gadducci, MD (1) · Antoine Italiano, MD (1) · Antonio Calles (1) · Armando Santoro, Prof. (1) · Bruno Vincenzi, Prof/MD (1) · Celestia Higano, M.D. (1) · Daniel Pink, PD Dr. med. (1)
PMID 33914350, PMID 33960681, PMID 37407274, PMID 29177975, PMID 39182994, PMID 40963055, PMID 10500494, PMID 11165136, PMID 19556318, PMID 19652065, PMID 20647340, PMID 21642514, PMID 21739119, PMID 22541893, PMID 22765965, PMID 23065525, PMID 24512981, PMID 24563480, PMID 24692579, PMID 25100135, PMID 25239225, PMID 26041763, PMID 26371143, PMID 28667207, PMID 30084934, PMID 30217671, PMID 30240327, PMID 31173362, PMID 31537908, PMID 31896519, PMID 31924332, PMID 32224306, PMID 32620635, PMID 32859662, PMID 33096421, PMID 33704620, PMID 33927108, PMID 34453241, PMID 34521554, PMID 34739582, PMID 35012962, PMID 35486638, PMID 35830841, PMID 36037567, PMID 36110934, PMID 36252599, PMID 36759720, PMID 37556023, PMID 39096398, PMID 39932221
2017 (2), 2023 (2), 2004 (1), 2009 (1), 2014 (1), 2016 (1), 2025 (1)